Ten years after the signing of ground-breaking licensing agreements between ViiV Healthcare and the Medicines Patent Pool (MPP), as well as ViiV’s direct agreements with Aurobindo Pharma, more than 1 billion packs of generic dolutegravir (DTG) based medicines have reached 24 million people living with HIV in 128 low- and middle-income countries (LMICs), transforming the HIV landscape in those areas of the world. This means that as of 2023, over 90% of people on antiretroviral treatment in these countries are estimated to be on DTG-based regimens.

The licence agreements have played a foundational role, enabling widespread access to TLD, (Tenofovir, Lamivudine, Dolutegravir - a WHO-preferred treatment for adults and adolescents), and in the development and availability of age-appropriate DTG-based treatment options for children and infants, addressing a key gap as children are disproportionately affected by HIV. As a result of the DTG paediatric licence, as well as a novel public-private partnership between ViiV, the Clinton Health Access Initiative (CHAI) and Unitaid providing technology transfer and regulatory support, generic dispersible tablet formulations of DTG have now been supplied to 95 LMICs for children weighing at least 3kg.

This session, hosted by MPP and Unitaid, unpacks key moments and lessons learned, and their relevance to emerging treatment and prevention therapies.